NuCana PLC at Jefferies London Healthcare Conference Transcript
Good afternoon. This is Eun Yang, a biotech analyst with Jefferies from New York. Our next presenting company is NuCana. NuCana is an oncology-focused company. And presenting from NuCana is Hugh Griffith, CEO and the founder of the company. Hugh?
Yes, good afternoon and a huge thank you to Eun and the wider Jefferies team for the invitation to present to you today. NuCana the name represents new cancer agents, and in particular, nucleotide analogs. I will be making forward-looking statements throughout this presentation, so, I would like to refer you to the disclaimer slide. Thanks.
So, what we're doing in NuCana is harnessing the power of phosphoramidate chemistry. And in so doing, we're creating these compounds that we call ProTides, and we believe they represent a new era in oncology. Traditionally, the pharmaceutical industry have developed nucleoside analogs for the treatment of cancer. And there are 16 FDA-approved anti-cancer nucleosides and over 20 FDA
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |